

INNOVATIVE MEDICINE FOR EVERYONE, EVERYWHERE

PRESS RELEASE

ADOCIA reports positive phase IIa clinical results on its fast-acting human insulin, HinsBet[®]: the first clinical results are confirmed on diabetic patients

The main results of this clinical trial are a rapid reduction of glycemia, an excellent local tolerance and an inter-patient and intra-patient variability, all comparable to NovoLog[®] (Novo Nordisk)

Lyon, 28th of February 2012, ADOCIA (ISIN: FR0011184241, Ticker: ADOC), a biotechnology company specialized in the formulation of therapeutic proteins for treating diabetes and chronic wounds (diabetic foot ulcers, venous ulcers), announces today positive results from a Phase IIa clinical trial evaluating the safety and efficacy of HinsBet[®], its fast-acting human insulin, in type 1 diabetic patients. This program is supported by OSEO.

This phase IIa study was a single center, double-blinded, randomized, cross-over trial conducted on 20 type 1 diabetic patients under euglycemic clamp procedure. The aim of the study was to compare pharmacokinetics, pharmacodynamics and safety of HinsBet[®] to the fast-acting insulin analog NovoLog[®], after 3 consecutive injections of each study medication to each patient.

The hypoglycemic effect of HinsBet[®] is as rapid as the one of NovoLog[®], one of the modern prandial insulins. Furthermore, neither serious adverse event nor clinically significant change in laboratory safety parameters occurred in this study. On local tolerance, HinsBet[®] was as good as NovoLog[®]. Finally, the inter and intra patients variabilities of the two medications after 3 consecutive injections are also similar on pharmacological parameters.

HinsBet[®] is a novel fast-acting formulation of recombinant human with BioChaperone[®], ADOCIA's proprietary technological platform. This polymer has been specifically designed by ADOCIA to form fully reversible molecular complexes with insulin or insulin analogs in order to accelerate the absorption and the glucose lowering effect of prandial insulins.

Olivier Soula, VP, R&D director and cofounder of ADOCIA, underlines: *"we have now the proof that our technology works in diabetic patients confirming the true potential of our technology for the diabetes treatment. HinsBet targets the same therapeutic performances of the rapid modern insulins with a cost advantage."*

Before launching a complete development plan, ADOCIA prepares an optimized formulation of HinsBet[®] for an additional Phase IIa by Q4 2012.


"Thanks to the success recorded amongst investors during our recent IPO, we now have a cash position of €36 million in early 2012 that will allow us to conduct all the clinical trials we have defined to license our product", concludes Gérard Soula, CEO and cofounder of ADOCIA.

ABOUT BIOCHAPERONE[®]

ADOCIA's BioChaperone[®] platform is a library of polysaccharides modified with naturally occurring molecules. These polymers are designed to form a reversible molecular complex with therapeutic proteins in order to solubilize and stabilize these proteins and to control their delivery.

A Phase IIa clinical trial including 198 diabetic patients suffering from foot ulcer in India is finished. A unique formulation of BioChaperone[®] with Platelet Derived Growth Factor BB applied every other day has been

This document may not be published, distributed or disseminated, directly or indirectly, in the United States of America, Canada, Australia, Italy or Japan



compared to Regranex[®] applied every day. This clinical trial is comparing BioChaperone[®] formulation, applied once every two days, to Regranex[®] applied every day.

ABOUT ADOCIA

A Biotech company founded by Gérard, Olivier and Rémi SOULA (Gérard SOULA is the founder of Flamel Technologies) in 2005, ADOCIA's mission is to create best-in-class drugs for the mass market from the innovative formulation of certain already-approved therapeutic proteins.

To date, ADOCIA has already carried out two collaborative development programs with Pharma majors. Furthermore, ADOCIA recently signed an exclusive worldwide license contract with a big pharma for the development of an ultra-fast insulin analog.

As well as the SOULA family, which is ADOCIA's main shareholder with close to 26% of the Company's capital, ADOCIA's shareholders include some of the largest investment funds specializing in innovation: Innobio and Bioam (managed by CDC Entreprises), IdInvest, Amundi, Viveris, Oréo Finance and SHAM.

For further information about ADOCIA, go to www.adocia.com



Gérard SOULA

CEO
ADOCIA

Tel.: +33 (0)4 72 610 610
contactinvestisseurs@adocia.com

NewCap.

Financial communication and investor relations
Axelle Vuillermet / Emmanuel Huynh
Tel.: +33(0)1 44 71 94 94
adocia@newcap.fr

Disclaimer

This press release and the information contained herein do not constitute an offer to subscribe to, or the solicitation of an offer to subscribe to, ADOCIA shares in any country. The distribution of this press release in certain countries may be subject to specific regulations. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

In particular:

This press release does not constitute an offer to subscribe to, or the solicitation of an offer to subscribe to, securities in the United States. The shares or any other securities of ADOCIA may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or exempt from registration. The shares of ADOCIA have not been, and will not be, registered under the U.S. Securities Act, and ADOCIA does not intend to make any public offer of its shares in the United States.

This press release is solely an advertisement, and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003, as amended, notably by Directive 2010/73/UE of the European Parliament and the Council of November 24 2010, and as transposed by the relevant member States of the European Economic Area (the "Prospectus Directive").

With respect to the member States of the European Economic Area that have implemented the Prospectus Directive, no action has been undertaken, or will be undertaken, to make an offer to the public for the securities requiring a publication by ADOCIA of a prospectus in any member State other than France. As a result, ADOCIA shares may not be offered in any member State other than France, except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been transposed by the relevant member State(s) or in any other circumstances not requiring ADOCIA to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in such member State(s).

This press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.

This document contains forward-looking information. No guarantee is given as to these forecasts being achieved, which are subject to risks including those described in the prospectus registered with the AMF with respect to the initial public offering of ADOCIA, and changes in economic conditions, the financial markets and the markets on which ADOCIA operates.

This document may not be published, distributed or disseminated, directly or indirectly, in the United States of America, Canada, Australia , Italy or Japan